Inhibition of Girdin enhances chemosensitivity of colorectal cancer cells to oxaliplatin

doi:10.3748/wjg.v20.i25.8229

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 25

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6468)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

478

WORD

335

HTML

3410

Figures (1-4)

289

Tables (1-2)

207

Sum=4719

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1027

Download

722

Sum=1749

Jul 7, 2014 (publication date) through Dec 29, 2024

Times Cited of This Article

Times Cited (23)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Jul 7, 2014; 20(25): 8229-8236
Published online Jul 7, 2014. doi: 10.3748/wjg.v20.i25.8229

Full Size Figure Download Figure

Figure 3 TOP2B as a downstream gene of Girdin is involved in the resistance of DLD1 cells to oxaliplatin. A: TOP2B mRNA level in DLD1 cells after infection with the Lv-Girdin shRNA; B: Growth inhibition of DLD1 cells by oxaliplatin in combination with adriamycin. ^aP < 0.05.

Citation: Zhang YJ, Li AJ, Han Y, Yin L, Lin MB. Inhibition of Girdin enhances chemosensitivity of colorectal cancer cells to oxaliplatin. World J Gastroenterol 2014; 20(25): 8229-8236
URL: https://www.wjgnet.com/1007-9327/full/v20/i25/8229.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i25.8229